Ethyl Cyanoacetate Market Projected to Reach USD 217.65 Million by 2032, Driven by Pharmaceutical and Organic Electronics Demand
Surging demand in organic synthesis and increasing usage in specialty chemicals and biodegradable products are propelling growth in the Ethyl Cyanoacetate market.
Austin, June 07, 2025 (GLOBE NEWSWIRE) -- The Ethyl Cyanoacetate Market Size was valued at USD 147.00 million in 2024 and is expected to reach USD 217.65 million by 2032, growing at a CAGR of 5.03% over the forecast period of 2025-2032.Download PDF Sample of Ethyl Cyanoacetate Market @ https://www.snsinsider.com/sample-request/7034
Growing Demand Across Pharmaceuticals and Cosmetics Drives the Expansion of Ethyl Cyanoacetate Applications in Safer Industrial Processes
Ethyl cyanoacetate demand is increasing as this intermediate is vital in the synthesis of pharmaceutical drugs and cosmetics. Between 2022 and 2024, its use in active pharmaceutical ingredients is projected to have risen by 12%, reflecting the increase in generic drugs production. In 2023, the American Chemical Society also reported that it was effectively used to improve cosmetics for skin health and anti-aging. Environment regulations in North America and Europe are driving the transition to safer chemical intermediates, which in turn, are amplifying utilization in a wide range of industries. Big producers like Eastman Chemical and BASF have spent, since 2022, increasing capacity in expectation of continued demand. Being widely used in health care, beauty, and industry, ethyl cyanoacetate is becoming a vital ingredient in worldwide manufacturing and product development.
The US Ethyl Cyanoacetate Market had the largest market share of 64% in 2024, growing at a CAGR of 4.62% over the forecast period of 2024-2032.
The U.S. ethyl cyanoacetate industry is rapidly expanding on account of increasing pharmaceutical and cosmetic production. Companies such as the FDA reported a rate of usage of Ethyl Cyanoacetate as an intermediate in drug and personal care products. DuPont and Ashland, amongst others, are heavily investing in R&D to improve product purity and efficiency, driving market growth.
Key Players:
Tiande Chemical Holdings Limited
Hebei Chengxin Co., Ltd.
Tokyo Chemical Industry Co., Ltd.
EMCO Dyestuff Pvt. Ltd.
Triveni Techno Chem
Shandong Xinhua Pharmaceutical Co., Ltd.
Tateyama Kasei Co., Ltd.
Loba Chemie Pvt. Ltd.
Sisco Research Laboratories Pvt. Ltd.
Merck KGaA
By Grade, the Pharmaceutical Grade Dominated the Ethyl Cyanoacetate Market in 2024 with a 45% Market Share.
This is because this active ingredient is a crucial precursor in producing a wide range of active pharmaceutical ingredients (APIs). For it is known, Ethyl Cyanoacetate is widely used in manufacturing cardiovascular and anti-inflammatory agents, according to the US FDA. We are pharmaceutical companies with pharmaceutical-grade Ethyl Cyanoacetate soda, because of its purity, the pharmaceutical industry has high purity and quality are very strict, and safety and efficacy of the products.
By Purity, 98% to 99% Dominated the Ethyl Cyanoacetate Market in 2024 with a 56% Market Share.
The supremacy is largely because in pharmaceuticals and cosmetics, this range of purity represents an excellent compromise between cost-effectiveness and performance. This grade is used to prepare high-purity fine chemicals, drug intermediates, etc., which require high purity but not ultra-pure conditions. For example, in the cosmetic industry, Ethyl Cyanoacetate of this purity is used in the manufacture of anti-aging and skin rejuvenation products, as cited in recent American Chemical Society articles. There is a preference among industrial users for this aliquot because of quality and consistency, as well. Manufacturers like Eastman Chemical, which are concentrating on streamlining production processes to address purity requirements quickly, help propel the segment.
By Function, the Chemical Intermediates Dominated the Ethyl Cyanoacetate Market in 2024 with a 38% Market Share.
Their use has continued to expand due to increased use in pharmaceutical and agrochemical preparations. Ethyl Cyanoacetate is a key precursor in the production of herbicides, insecticides and medicinal molecules etc. For instance, BASF's agrochemical segment has increased use of Ethyl Cyanoacetate intermediates for environment-friendly pesticide development, as environmental apprehensions escalate. The sector is also helped by progress in green chemistry, with encouragement for safer intermediate chemicals. All these factors together make chemical intermediates the largest among the functional segments.
Buy Full Research Report on Ethyl Cyanoacetate Market 2025-2032 @ https://www.snsinsider.com/checkout/7034
North America dominated the Ethyl Cyanoacetate Market in 2024, Holding a 38.5% Market Share.
This dominance can be ascribed to the strong presence of the pharmaceutical industry, high healthcare spending, and key chemical producers in the region. The streamlined & revised US drug policy has led to quicker drug approvals, in turn driving the demand for Ethyl Cyanoacetate in API synthesis. Eastman Chemical and DuPont have large manufacturing operations here, providing a dependable supply. In addition, increasing consumer knowledge about the personal care and beauty products that contain Ethyl Cyanoacetate has fueled the demand from the cosmetics industry. These conditions, as a group, solidify North America's position as the leading region.
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June
The average healthcare stock has a yield of just 1.7%. Medtronic's dividend yield is 3.3%. Alexandria Real Estate Equities' yield is 7.4%. 10 stocks we like better than Medtronic › The healthcare sector isn't exactly known for offering huge yields, with Health Care Select Sector SPDR (NYSEMKT: XLV) offering a yield of just 1.7%. If dividend investors take some time to dig into the sector, however, they can do much better. For example, Medtronic (NYSE: MDT) has a 3.3% yield today, and Alexandria Real Estate Equities (NYSE: ARE) is offering a yield of 7.4%. Here's what you need to know about each of these high-yield healthcare stocks. Medtronic makes medical devices. It is one of the largest competitors in the space, making products across the cardiovascular, neuroscience, medical surgical, and diabetes categories. It has a leading position in each of the areas in which it operates, and it operates on a global scale. That said, the last few years haven't been the best ones for the company. Innovation, which is highly important in the healthcare space, can be lumpy. And given Medtronic's size, the business has become a little cumbersome. Growth has stalled out, and profitability has come under pressure. Investors have focused on the negatives pushing the shares lower and the dividend yield up toward the high end of Medtronic's historical yield range. If you are a dividend investor that thinks in decades and not days, however, this is likely to be an investment opportunity. The company's innovation pipeline is starting to turn into new-product introductions. As new products gain traction, financial performance is likely to improve. And management has been working to streamline the business with cost cuts and a move to refocus on its most profitable operations. To that end, the company is set to spin off its lower-margin diabetes division in 2026. The move is expected to be immediately accretive to earnings, and the dividend policy isn't expected to change. All in, Medtronic is doing what it needs to do to get back on the growth path. And that should support continued dividend increases; the medical device maker only has two years to go before it hits Dividend King status (50+ years of annual dividend increases). June could be an opportune time to buy the stock hand over fist. Alexandria is a real estate investment trust (REIT), which seems pretty far away from healthcare. Its primary focus is on office properties, which also seems a bit removed from healthcare. The key here is that the REIT owns biomedical research facilities, which combine research space and office space in one property. Both are important to each other since the research takes place in specialized space, while the analysis of that research takes place in a normal office environment. Alexandria is one of the largest pure play medical research REITs you can buy. Alexandria counts some of the largest and most important medical research groups as tenants, from both the private side of the equation and the government side. However, like any landlord, the REIT's revenues will be impacted by the occupancy levels of its properties. And those rise and fall over time. Right now, occupancy is relatively weak, dropping to 91.7% at the end of the first quarter of 2025 from 94.6% at the end of 2024. Swings like this happen from time to time, but Wall Street is treating Alexandria as if its dividend is at a material risk of being cut. Only the funds from operations (FFO) payout ratio in the first quarter was a fairly strong 57%. There's room for adversity before a dividend cut would be in order. To be fair, office properties, and particularly highly specialized office properties, tend to have higher operating costs than other real estate assets. But it seems highly likely that Alexandria will manage its way through this weak patch and continue to extend its 15-year streak of annual dividend increases. For income lovers, this healthcare REIT is worth a deep dive in June. The average healthcare stock has an uninspiring dividend yield. But the average is made up of many different companies, some of which actually have very attractive dividend yields. That list includes industry-leading companies like Medtronic and Alexandria Real Estate. You might just want to pick up shares in one, or both, of these high yielders before June is over after you get to know them a little better. Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Reuben Gregg Brewer has positions in Medtronic. The Motley Fool has positions in and recommends Alexandria Real Estate Equities. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. 2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Why Volkswagen is convinced Waymo and Tesla are vulnerable in the $500 billion robotaxi race — ‘not a winner take all market'
The German carmaker is preparing to enter the market for autonomous ride-hailing services next year with its Volkswagen ID. Buzz AD. But instead of competing against existing transportation providers, it aims to work with them as a partner. The different approach comes amid continued popular resentment towards robotaxis. When Big Tech first began deploying self-driving cars to San Francisco two years ago, companies encountered something unusual—popular resistance. Angry residents would sabotage the robotaxis with the help of traffic cones, while the city's fire department chief herself would regularly malign them as a dangerous nuisance. Even today, during the recent outbreak of civil unrest in Los Angeles over mass deportations, protesters caused hundreds of thousands of dollars when they deliberately torched Waymo cars. One old economy company preparing to enter the autonomous ride-hailing space is taking a completely different approach when it launches next year. Germany's Volkswagen is wagering society at large is increasingly fed up with the collateral damage left behind by Silicon Valley's move-fast-and-break-things mentality. 'Our approach is different—we deliberately want to act as partners that build upon existing infrastructure,' VW Group executive Sascha Meyer told Fortune during a test drive of its robotaxi. 'A key point for social acceptance we believe is being a service provider whose presence is desired precisely because we will not be competing with systems already in place.' This week, VW revealed the series production version of its autonomous ride-hailing cab based on its retro-styled VW ID. Buzz EV microbus. Packaged together with the requisite fleet management software and digital customer booking platform, it wants to offer local transportation authorities and other commercial fleets a turnkey solution that can be integrated effortlessly into their service. While a Waymo or a Tesla plan to compete with existing providers, the German carmaker aims to be an equal partner working hand in glove with communities that want their help. Even if the first roughly 500 vehicles won't be deployed to Uber for use in Los Angeles until next year, VW believes the race for market share is only just beginning. It's convinced there will be more than enough demand to grab a bite out of the €350 billion-€450 billion in revenue McKinsey projects for autonomous ride-hailing services in North America and Europe by 2035. That's more than half a trillion dollars worth of growth over the next 10 years, potentially. Meyer runs MOIA, the mobility services subsidiary of the VW Group which will offer a high-tech version of the zero-emission Volkswagen ID. Buzz electric minivan complete with the backend software ecosystem around it. Fortune had a chance to ride along with Meyer in one as the robotaxi navigated its way—with a safety driver behind the wheel at all times—through the busy streets of Hamburg. Here in Germany's second-largest city, Volkswagen has quietly been testing the technology for several years now thanks to the active support of city officials. The white label service Volkswagen has in mind means all customers need to do is slap their logo on the vehicle and adorn the customer-facing front end with their respective corporate identity and they are ready to go. The group's go-to-market strategy heavily incorporates public transit authorities, an approach influenced by its European roots. With their extensive wealth of well-built mass transit networks, these mainly state and municipal-owned companies play a role in urban, suburban and ex-urban mobility so crucial it would be difficult to displace them. Take for example the BVG authority operated by the German capital of Berlin, with whom VW Group already has signeda letter of intent. Three million people entrust their everyday transportation needs to its fine meshed web of buses, streetcars, subways and commuter trains to get back and forth in the greater metropolitan area every day. A BVG-branded robotaxi integrated into its service should see far faster adoption than were Volkswagen to compete alongside it. In a way, VW's partnership approach to the market is a natural fit. Carmakers have decades of experience working closely with regulators from various agencies, state and federal, to ensure their cars conform with traffic safety and environmental standards. In Silicon Valley, however, regulators are often viewed with suspicion—at best an irritant, at worst the enemy. The debacle around robotaxi developer Cruise proved that: following a fateful October 2023 accident in San Francisco, the tech startup deliberately withheld crucial information from crash investigators, shattering what trust was placed in them by the state of California only weeks earlier. When Cruise owner General Motors found out, it acted swiftly to sideline the CEO, but by then it was too late and the reputational damage was done. Cruise ceased all operations and GM pulled out of the autonomous ride-hailing race in December. With crosstown rival Ford already giving up even earlier, only Volkswagen and Hyundai, through its Motional subsidiary, still remain in contention from the legacy car industry. The rest are AI tech companies like Waymo, Tesla, Amazon subsidiary Zoox as well as their foreign equivalents like China's Baidu and Wayve in the UK. Of course, Meyer knows that the competition has a head start they won't hand over willingly. 'Waymo has an indisputable lead, that's clear, and I don't believe they're going to slow down in any way,' he told Fortune. Then there's Tesla, which is gearing up to launch its own pilot in Austin due to launch Sunday. While Meyer readily admits it's likely only a matter of time until Tesla can graduate to a full commercial robotaxi service, he believes all is not lost. For one, neither is present in Europe, a market known for being far more risk-averse towards unproven technologies and quick to regulate against threats towards public safety. Tesla's vaunted Full Self-Driving (FSD) feature, a software stack that will imbue its robotaxis with the requisite intelligence, hasn't yet been approved for use anywhere on the continent. In fact, it's not even available as an advanced driver assist. This offers enough of an opportunity for Volkswagen to greenlight the production of at least 10,000 robotaxi vehicles, potentially more. And even if Waymo and Tesla do retain their lead by the time VW is ready, Meyer believes communities will demand some degree of healthy competition among autonomous ride hailing providers in order to ensure an optimum service for a low cost. 'No one, not even in the United States, will be happy if there's a monopoly,' he said. 'We don't believe it will be a winner-takes-all market.' This story was originally featured on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
Tulare County home listings asked for less money in May - see the current median price here
The median home in Tulare County listed for $419,975 in May, slightly down from the previous month's $421,778, an analysis of data from shows. Compared to May 2024, the median home list price slightly decreased from $424,975. The statistics in this article only pertain to houses listed for sale in Tulare County, not houses that were sold. Information on your local housing market, along with other useful community data, is available at Tulare County's median home was 1,774 square feet, listed at $244 per square foot. The price per square foot of homes for sale is up 1.6% from May 2024. Listings in Tulare County moved steadily, at a median 44 days listed compared to the May national median of 51 days on the market. In the previous month, homes had a median of 43 days on the market. Around 352 homes were newly listed on the market in May, a 15% increase from 306 new listings in May 2024. The median home prices issued by may exclude many, or even most, of a market's homes. The price and volume represent only single-family homes, condominiums or townhomes. They include existing homes, but exclude most new construction as well as pending and contingent sales. In California, median home prices were $775,000, a slight increase from April. The median California home listed for sale had 1,775 square feet, with a price of $477 per square foot. Throughout the United States, the median home price was $440,000, a slight increase from the month prior. The median American home for sale was listed at 1,840 square feet, with a price of $234 per square foot. The median home list price used in this report represents the midway point of all the houses or units listed over the given period of time. Experts say the median offers a more accurate view of what's happening in a market than the average list price, which would mean taking the sum of all listing prices then dividing by the number of homes sold. The average can be skewed by one particularly low or high price. The USA TODAY Network is publishing localized versions of this story on its news sites across the country, generated with data from Please leave any feedback or corrections for this story here. This story was written by Ozge Terzioglu. Our News Automation and AI team would like to hear from you. Take this survey and share your thoughts with us. This article originally appeared on Visalia Times-Delta: Tulare County home listings asked for less money in May - see the current median price here
